Navigation Links
DSM Recognized With Profiles in Sustainability Award for Corporate Commitment to Sustainability and Innovations for Pharmaceutical Manufacturing
Date:2/9/2011

PARSIPPANY, N.J., Feb. 9, 2011 /PRNewswire/ -- DSM Pharmaceutical Products, the pharmaceutical manufacturing organization within Royal DSM N.V. (DSM KON, Euronext), a global Life Sciences and Materials Sciences company, and #1 on the Dow Jones Sustainability Index 2010, was recognized in the category of "Product, Process and Green Innovations" at InformexUSA, where the award was announced yesterday in Charlotte, North Carolina.DSM was considered based on its corporate commitment and ongoing innovations in pharmaceutical manufacturing for the sustainable, cost-effective production of active pharmaceutical ingredients and intermediates.  In 2010, as part of this continued commitment, DSM launched InnoSyn™ route scouting services in response to the increasing interest of pharmaceutical customers to outsource the development of robust low-cost manufacturing routes.  DSM's route scouting capabilities can lead to significant cost savings and a better environmental footprint by the reduction of synthesis steps or redesign of synthesis routes using "innovative synthesis".

DSM's InnoSyn™ route scouting supports the research and development initiatives of pharmaceutical companies by integrating the full range of DSM competencies such as biocatalysis, homogeneous catalysis, micro reactor technology and other advanced synthesis methods that speed up feasibility studies.  DSM's rapid screening and scale-up also provide robust, cost-effective 'next generation' manufacturing solutions important for drug life cycle management focusing on cost reduction.  In October 2010, DSM was recognized with a European Outsourcing Award for "Most Improved Process" with the submission of a customer success story entitled, "Achieving substantial carbon dioxide footprint reduction for the scale up of a drug intermediate", in which DSM identified a faster, 3-step route with the same reliability and stable quality as the original 7-step process, with a carbon footprint reduction of over 50%.

Alexander Wessels, President and CEO of DSM Pharmaceutical Products, stated, "DSM is committed to continuous innovation to provide ever more-efficient and sustainable alternatives, and we are proud to offer such viable manufacturing solutions for the future of pharmaceuticals.  As a manufacturing partner to the pharmaceutical industry, we make a commitment to employ expertise across our organization to achieve success for our unique customer challenges.  DSM is driving sustainability for both small and large molecule production.  Route scouting is part of DSM's "green chemistry toolbox" which also integrates process intensification activities, such as micro reactor technology, that increase yield and reduce waste for small molecules.  And we apply similar concepts in biotechnological manufacturing with our XD® and Rhobust™ technologies that minimize production volumes and process steps, resulting in higher plant utilization and less labor.  Additionally, we are employing DSM's microbial fermentation for a range of enzyme production."  Luca Mantovani, President and Business Unit Director of DSM Pharma Chemicals, explained, "A large number of complex chemical steps need to take place in traditional pharmaceutical manufacturing.  Optimizing first generation and next generation processes by driving down the cost curve is crucial for the commercial success of pharmaceutical compounds – both those new to the market and those being considered for life cycle extension."

DSM also exhibited as part of InformexUSA and gave two presentations on "(Bio)Catalyst screening for faster design of sustainable manufacturing routes" and "Turning Green Chemistry and Sustainability into Business Drivers."  The Profiles in Sustainability awards are given by United Business Media Limited, a global business media company and parent of InformexUSA.

InnoSyn™ is a trademark of Royal DSM N.V.

DSM Pharmaceutical ProductsDSM Pharmaceutical Products is a global provider of high quality custom contract manufacturing and development services to the pharmaceutical and biopharmaceutical industries.  DSM contract manufacturing services include: chemical development, registered intermediates, registered starting materials, active pharmaceutical ingredients (API's), mammalian cell production of monoclonal antibodies and proteins, formulation development, clinical trial manufacturing and finished dose form manufacturing of solids, semi-solids, and scheduled drugs, aseptic liquid and lyophilized products.  More information: www.dsmpharmaceuticalproducts.com

DSM – the Life Sciences and Materials Sciences CompanyRoyal DSM N.V. creates solutions that nourish, protect and improve performance.  Its end markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrical and electronics, life protection and housing.  DSM manages its business with a focus on the triple bottom line of economic performance, environmental quality and social responsibility, which it pursues simultaneously and in parallel.  DSM has annual net sales of about euro 8 billion and employs some 22,700 people worldwide.  The company is headquartered in the Netherlands, with locations on five continents.  DSM is listed on Euronext Amsterdam.  More information: www.dsm.comFor more information:DSM Corporate Affairs North America

Hugh Welsh

Tel +1 973-257-8208

Email hugh.welsh@dsm.com

DSM Pharmaceutical Products

Guy Tiene

Tel +1 973-257-8160

Email guy.tiene@dsm.comDSM Forward-looking statementsThis press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.


'/>"/>

SOURCE DSM Pharmaceutical Products
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Shire Recognized by ISPE Facility of the Year Awards Program
2. CardioMEMS Recognized by Georgia Bio for Pivotal Strategic Partnership
3. Dr. Marianne T. Sweetser Recognized by Strathmores Whos Who Worldwide Publication
4. LuxteL Brand Is the Longest Standing Recognized Name in the Industry
5. Abbott Again Recognized for Environmental Initiatives in Illinois
6. Atrium Recognized by New Hampshire Bio/Medical Council
7. Point-of-Care Partners Recognized for Role in Managing SEMI
8. HistoRx Recognized as a 2010 Company to Watch by the Connecticut Technology Council
9. Duluth-Area Plasma Donors to be Recognized for Lifesaving Contribution in Fight Against Rare Diseases
10. Precision Therapeutics President and CEO Sean McDonald Recognized as a Leading Business Executive and Recipient of 2010 Pacesetters Award
11. Lilly Recognized with World Business and Development Award for Tuberculosis Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... 2016 Mast Therapeutics, Inc. (NYSE MKT: ... cell disease and heart failure, today announced that it intends ... common stock in an underwritten public offering.  The offering is ... no assurance as to whether or when the offering may ... of the offering.   --> ...
(Date:2/9/2016)... The global prefilled syringes market accounted for ... to grow with a CAGR of 12.9% during 2015-2020. ... dominated the global prefilled syringes market, with 90.1% share ... The global market of prefilled syringes is up ... population, increasing demand for vaccines, increasing prevalence of chronic ...
(Date:2/9/2016)... The life of Dr. Jan Vilcek , celebrated immunologist ...  Twists of fate, combined with sheer grit, brought him from ... communist Czechoslovakia to New York City ... history by playing a key role in the development of ...  Dr. Vilcek brings readers along his improbable journey in his ...
Breaking Medicine Technology:
(Date:2/9/2016)... ... February 09, 2016 , ... Sir ... company , is proud to announce that many of their franchises have received ... service. The hard surface restoration franchises received customer recognition through positive reviews and ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... CURE ... patients, has officially launched the Multiple Myeloma Heroes Awards event , which will ... in the lives of patients with MM. The MM Heroes Awards nomination process ...
(Date:2/8/2016)... ... 08, 2016 , ... Stephanie Hebert Insurance Agency, serving families ... new charity campaign. As part of their ongoing community involvement program, funds are ... that children deserve a voice, and in the spirit of neighbors helping neighbors ...
(Date:2/8/2016)... ... February 08, 2016 , ... If you are feeling that your clothes are ... alone. According to the Center for Disease Control and Prevention (CDC), 34.9% of U.S. ... certain types of cancer, some of the leading causes of preventable death. February ...
(Date:2/8/2016)... ... February 08, 2016 , ... Local insurance agency ... Venice, FL area, has initiated a fundraiser for a two year old little ... days after Christmas. To support this beautiful child who is facing life’s journey ...
Breaking Medicine News(10 mins):